Azide-PEG5-Tos

What We Offer

Azide-PEG5-Tos

Azide-PEG5-Tos | 236754-49-7

Catalog Number R14-0191
Category Azides
Molecular Formula C17H27N3O7S
Molecular Weight 417.48
Catalog Number Size Price Quantity
R14-0191 -- $--

Product Introduction

Azide-PEG5-Tos is a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Chemical Information

Synonyms 14-Azido-3,6,9,12-tetraoxatetradecyl 4-methylbenzenesulfonate
Purity >98.0%
Shelf Life ≥ 2 years
IUPAC Name 2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate
Canonical SMILES CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCOCCN=[N+]=[N-]
InChI InChI=1S/C17H27N3O7S/c1-16-2-4-17(5-3-16)28(21,22)27-15-14-26-13-12-25-11-10-24-9-8-23-7-6-19-20-18/h2-5H,6-15H2,1H3
InChI Key RCRFPWKHJGMATE-UHFFFAOYSA-N
Solubility 10 mm in DMSO
Appearance Solid Power
LogP 0.88
  • Product Specification
  • Application
Storage Store at -20 °C, keep in dry and avoid sunlight.

Azide-PEG5-Tos is widely utilized in the field of bioconjugation, serving as a crucial component for linking biomolecules in a site-specific manner. Its unique azide group allows for the efficient attachment to various functional groups via click chemistry, particularly the Huisgen cycloaddition reaction with alkynes. This feature is especially advantageous in the synthesis of antibody-drug conjugates (ADCs), where precise conjugation is essential for maintaining the biological activity of the antibodies while enhancing the therapeutic efficacy of the drugs. By employing Azide-PEG5-Tos, researchers can achieve high specificity and yield in the formation of ADCs, facilitating the development of more effective cancer therapies.

Another significant application of Azide-PEG5-Tos lies in the realm of drug delivery systems. The PEGylation of therapeutic agents using this compound can improve their solubility and stability, prolonging their circulation time in the bloodstream. This is particularly important for hydrophobic drugs, which often face challenges related to bioavailability and toxicity. By incorporating Azide-PEG5-Tos into drug formulations, pharmaceutical scientists can create nanoparticles or liposomes that encapsulate the drug while simultaneously providing a stealth effect against the immune system. This enhances the therapeutic index of the drugs and reduces side effects, leading to better patient outcomes.

Azide-PEG5-Tos is also instrumental in the development of diagnostic tools, particularly in the area of imaging and biomarker detection. By conjugating this compound to imaging agents or probes, researchers can improve the targeting and localization of these agents within biological systems. For instance, the azide group allows for the covalent attachment of fluorophores or radiolabels to biomolecules, enhancing their visibility in various imaging modalities such as fluorescence microscopy or positron emission tomography (PET). This targeted approach not only improves the sensitivity of detection but also enables real-time monitoring of disease progression and treatment response.

Lastly, Azide-PEG5-Tos has applications in the creation of advanced biomaterials. The ability to functionalize surfaces with this compound allows for the development of smart materials that can respond to specific stimuli, such as changes in pH or temperature. By incorporating bioactive molecules or drugs onto the surface of these materials through the azide-PEG link, researchers can create systems that release therapeutic agents in a controlled manner. This is particularly valuable in tissue engineering and regenerative medicine, where spatial and temporal control over drug release is critical for promoting tissue repair and regeneration. The versatility of Azide-PEG5-Tos in crafting such innovative biomaterials holds great promise for future therapeutic strategies.

Computed Properties

XLogP3 1.9
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 9
Rotatable Bond Count 17
Exact Mass 417.15697138 g/mol
Monoisotopic Mass 417.15697138 g/mol
Topological Polar Surface Area 103Ų
Heavy Atom Count 28
Formal Charge 0
Complexity 527
Isotope Atom Count 0
Defined Atom Stereocenter Count 0
Undefined Atom Stereocenter Count 0
Defined Bond Stereocenter Count 0
Undefined Bond Stereocenter Count 0
Covalently-Bonded Unit Count 1
Compound Is Canonicalized Yes

Patents

Publication NumberTitlePriority Date
WO-2022056273-A1 Lipid conjugates for the delivery of therapeutic agents 2020-09-11
WO-2020113233-A1 Irak degraders and uses thereof 2018-11-30
AU-2019389174-A1 Irak degraders and uses thereof 2018-11-30
BR-112021010484-A2 Irak degraders and their uses 2018-11-30
CN-113423427-A IRAK degraders and their uses 2018-11-30
cartIcon
Inquiry Basket